Amgen 2007 Annual Report Download - page 107

shareholders. The Amended and Restated 1993 Equity Incentive Plan terminated on March 11, 2003 and no
shares are available for issuance under the 1993 Plan for future grants.
(3) This plan was assumed by Amgen in connection with the merger of Tularik with and into Amgen SF, LLC,
a wholly owned subsidiary of Amgen, on August 13, 2004. This plan was previously approved by Tularik’s
shareholders.
(4) These plans were assumed by Amgen in connection with the merger of Abgenix with and into Amgen Fre-
mont Inc., a wholly owned subsidiary of Amgen, on April 1, 2006. The Amended and Restated 1996 Stock
Incentive Plan (the “1996 Plan”) was previously approved by Abgenix’s shareholders. The 1996 Plan
terminated on July 16, 2006. Although there are options still outstanding under the 1996 Plan, no shares are
available for issuance for future grants.
(5) This plan was assumed by Amgen in connection with the merger of Avidia with and into Amgen Mountain
View Inc., a wholly owned subsidiary of Amgen, on October 24, 2006. This plan was terminated on No-
vember 23, 2006 and although there are options still outstanding under this plan, no shares are available for
issuance for future grants.
(6) This plan was assumed by Amgen in connection with the acquisition of Ilypsa on August July 18, 2007.
This plan was terminated on August 17, 2007 and although there are options still outstanding on this plan,
no shares are available for issuance for future grants.
(7) As of December 31, 2003, there were no further offerings under the Amgen Limited Sharesave Plan and the
last share purchase under this plan was March 31, 2003.
(8) Although 300,000 shares of common stock are authorized for issuance under the Amgen Limited 2000 U.K.
Company Employee Share Option Plan, no shares have been issued under this plan.
(9) The Amgen Technology Ireland Irish Tax Approved Share Plan was approved by the Board of Directors on
March 7, 2007 and 7,832 shares were purchased on March 26, 2007.
Summary of Equity Compensation Plans Not Approved by Stockholders
The following is a summary of the equity compensation plans, which have shares available for issuance for
future grants as of December 31, 2007 and were adopted or assumed by the Board of Directors without the
approval of our stockholders:
Amended and Restated 1999 Equity Incentive Plan
The Amended and Restated 1999 Equity Incentive Plan (formerly known as the Immunex Corporation 1999
Stock Option Plan) (the “1999 Plan”) was assumed pursuant to the terms of the merger agreement between the
Company and Immunex which was approved by the Company’s stockholders in May 2002. The plan was pre-
viously approved by Immunex’s shareholders. The 1999 Plan consists of two articles — Article I which governs
awards granted prior to July 15, 2002 (the “Restatement Date”) and Article II which governs awards granted on
or after the Restatement Date. As the terms of Stock Awards (as defined below) made pursuant to the 1999 Plan
going forward are governed exclusively by Article II of the plan, the following is a description of the material
provisions of Article II of the 1999 Plan. This description is qualified in its entirety by reference to the 1999 Plan
itself, which was filed as an exhibit to the Company’s Form S-8 dated July 16, 2002.
Stock Subject to the 1999 Plan. Subject to adjustments upon certain changes in the common stock, the
shares available for issuance under the 1999 Plan upon exercise of the outstanding grants made pursuant to the
1999 Plan are Amgen’s common stock. The number of shares authorized for issuance under the 1999 Plan is
19,273,852. Awards of (i) incentive stock options, (ii) nonqualified stock options, (iii) stock bonuses and iv)
rights to purchase restricted stock (“Stock Award”) may be granted under the 1999 Plan.
Administration. The 1999 Plan is administered by the Board of Directors. The Board of Directors has dele-
gated administration of the 1999 Plan to the committees of the Board of Directors.
95